- Home
- GNPX vs DWTX Comparison
GNPX vs DWTX Comparison
Compare GNPX & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- DWTX
- Stock Information
- Founded
- GNPX 2009
- DWTX 2012
- Country
- GNPX United States
- DWTX United States
- Employees
- GNPX N/A
- DWTX N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- DWTX
- Sector
- GNPX Health Care
- DWTX
- Exchange
- GNPX Nasdaq
- DWTX NYSE
- Market Cap
- GNPX 6.1M
- DWTX 5.9M
- IPO Year
- GNPX 2018
- DWTX N/A
- Fundamental
- Price
- GNPX $0.38
- DWTX $4.20
- Analyst Decision
- GNPX Strong Buy
- DWTX
- Analyst Count
- GNPX 1
- DWTX 0
- Target Price
- GNPX $10.00
- DWTX N/A
- AVG Volume (30 Days)
- GNPX 6.0M
- DWTX 3.1M
- Earning Date
- GNPX 05-13-2025
- DWTX 03-31-2025
- Dividend Yield
- GNPX N/A
- DWTX N/A
- EPS Growth
- GNPX N/A
- DWTX N/A
- EPS
- GNPX N/A
- DWTX N/A
- Revenue
- GNPX N/A
- DWTX N/A
- Revenue This Year
- GNPX N/A
- DWTX N/A
- Revenue Next Year
- GNPX N/A
- DWTX N/A
- P/E Ratio
- GNPX N/A
- DWTX N/A
- Revenue Growth
- GNPX N/A
- DWTX N/A
- 52 Week Low
- GNPX $0.22
- DWTX $1.62
- 52 Week High
- GNPX $4.09
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- GNPX 43.09
- DWTX N/A
- Support Level
- GNPX $0.22
- DWTX N/A
- Resistance Level
- GNPX $0.39
- DWTX N/A
- Average True Range (ATR)
- GNPX 0.06
- DWTX 0.00
- MACD
- GNPX 0.00
- DWTX 0.00
- Stochastic Oscillator
- GNPX 31.23
- DWTX 0.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.